ATM mutations and high-risk prostate cancer have been associated in some studies through screening of patients with advanced disease [28,29], although BRCA2 remains the only gene in which pathogenic variants have been consistently linked to aggressive prostate cancer. This evidence concerns the gene ATM and prostate cancer.